PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

http://ww2.peerviewpress.com

subscribe
share






Amy Goodrich, CRNP - Making Modern Treatment Choices in CLL: Oncology Nurse Insights on the Patient Journey and the New Era of Care


Go online to PeerView.com/GKP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this replay of a webcast during the 2021 ONS Congress, Amy Goodrich, CRNP, Josie Montegaard, MSN, AGNP-BC, and Lisa Nodzon, PhD, ARNP, AOCNP, discuss practical applications of the latest evidence on targeted therapeutics to nursing care in CLL, as they present a rich collection of clinical examples from nursing practice. A patient video testimonial on the nurse–patient relationship and the key role of nurses as patient educators during the therapeutic journey is also featured. Upon completion of this accredited CE activity, participants should be better able to: Cite the clinical signs, relevant prognostic factors, and patient- or disease-related features that influence treatment selection for CLL, Summarize updated clinical efficacy and safety evidence surrounding novel therapeutic classes in CLL, including BTK and BCL-2 inhibitors, novel antibodies, and cell therapy, Develop educational strategies for patients with CLL related to therapeutic expectations, safety considerations, sequential treatments, and differences among novel agent classes, Manage dosing and safety considerations for patients with CLL receiving BTK or BCL-2 inhibitors, novel antibodies, or other approaches to treatment.


fyyd: Podcast Search Engine
share








 June 19, 2021  1h2m